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Purpose of the study
In order to explore a possible pathogenetic mechanism of
abacavir (ABC) cardiovascular toxicity, we assess the
impact of beginning the drug on endothelial function via
assessment of brachial artery diameter (BAD) and flow-
mediated dilation (FMD).
Methods
Cross-sectional observational study that included all con-
secutive HIV-infected patients seen at a metabolic clinic
who had BAD and FMD evaluation before and 9 months
after beginning ABC as a component of a new drug regi-
men.
Summary of results
There were no overt metabolic, virological or antiretrovi-
ral drug-related factors associated with BAD and FMD
change over time among patients starting ABC. (Figure 1)
Conclusion
Change in impairment of functional integrity of the vas-
culature is not an associated factor related with ABC use.
Cardiovascular disease risk among HIV-infected HAART-
experienced persons is likely governed by complex patho-
physiologic and treatment factors.
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